Grifols (GRFS) Cash from Investing Activities (2010 - 2020)
Grifols' (GRFS) quarterly Cash from Investing Activities came in at -$125.1 million in Q1 2020, up 56.61% YoY from -$79.9 million in Q2 2019, and up 71.26% on a QoQ basis from -$435.2 million in Q4 2019.
Grifols (GRFS) Cash from Investing Activities (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Cash from Investing Activities data on file, last reported at -$125.1 million in Q1 2020.
- Quarterly Cash from Investing Activities rose 56.61% year-over-year to -$125.1 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$94.3 million (down 223.87% YoY) and the FY2025 annual result came in at -$674.0 million, down 171.19% from the prior year.
- Cash from Investing Activities climbed to -$125.1 million in Q1 2020, from -$435.2 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $2.4 billion in Q4 2017 to a low of -$798.7 million in Q3 2016.
- A 5-year average of $281.0 million and a median of -$120.2 million in 2016 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2016 — Cash from Investing Activities sank 1045.5% — and 2017, when it soared 2116.99%.
- Tracing GRFS's Cash from Investing Activities over 5 years: stood at -$120.2 million in 2016, then soared by 2116.99% to $2.4 billion in 2017, then plunged by 68.9% to $754.2 million in 2018, then slumped by 157.7% to -$435.2 million in 2019, then jumped by 71.26% to -$125.1 million in 2020.
- The last three Cash from Investing Activities figures came in at -$125.1 million (Q1 2020), -$435.2 million (Q4 2019), and -$288.3 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -2.91 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -569.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.35 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.11 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -125.09 Mn |
| Mar 31, 2020 | -125.09 Mn |
| Dec 31, 2019 | -435.16 Mn |
| Dec 31, 2019 | -435.16 Mn |
| Mar 31, 2019 | -288.25 Mn |
| Mar 31, 2019 | -288.25 Mn |
| Dec 31, 2018 | 754.17 Mn |
| Dec 31, 2018 | 754.17 Mn |
| Jun 30, 2018 | -509.49 Mn |
| Jun 30, 2018 | -509.49 Mn |
| Mar 31, 2018 | 119.73 Mn |
| Mar 31, 2018 | 119.73 Mn |
| Dec 31, 2017 | 2.43 Bn |
| Dec 31, 2017 | 2.43 Bn |
| Jun 30, 2017 | 88.45 Mn |
| Jun 30, 2017 | 88.45 Mn |
| Mar 31, 2017 | 1.98 Bn |
| Mar 31, 2017 | 1.98 Bn |
| Dec 31, 2016 | -120.24 Mn |
| Dec 31, 2016 | -120.24 Mn |